## IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

FERRING PHARMACEUTICALS INC., REBIOTIX INC.	) ) )
Plaintiffs,	<i>)</i> )
v.	) ) C.A. No. 21-1694-JLH
FINCH THERAPEUTICS GROUP, INC., FINCH THERAPEUTICS, INC., and FINCH THERAPEUTICS HOLDINGS, LLC.	) C.A. No. 21-1094-JLH ) ) )
Defendants.	) )
FINCH THERAPEUTICS GROUP, INC., FINCH THERAPEUTICS, INC., FINCH THERAPEUTICS HOLDINGS, LLC, and REGENTS OF THE UNIVERSITY OF MINNESOTA	) ) ) ) )
Counterclaim-Plaintiffs/Reply Defendants,	) )
v.	, )
FERRING PHARMACEUTICALS INC., and REBIOTIX, INC.	, ) ) )
Counterclaim-Defendants/Reply Plaintiffs.	, ) )

## FERRING/REBIOTIX'S RENEWED MOTION FOR JUDGMENT AS A MATTER OF LAW

As allowed under Federal Rule of Civil Procedure 50(b), Ferring Pharmaceuticals Inc. and Rebiotix (collectively, "Ferring") respectfully renew their motion for judgment as a matter of law ("JMOL") made during trial under Federal Rule of Civil Procedure 50(a) on the following issues:

- 1. No reasonable jury would have had a legally sufficient evidentiary basis to find that Finch Therapeutics Group, Inc., Finch Therapeutics, Inc., Finch Therapeutics Holdings, LLC (collectively, "Finch") and the Regents of the University of Minnesota ("UMN" and collectively with Finch, "Finch/UMN") proved by a preponderance of the evidence that Ferring infringes asserted claim 7 of United States Patent Number 10,251,914 ("the '914 patent");
- 2. No reasonable jury would have had a legally sufficient evidentiary basis to find that Finch/UMN proved by a preponderance of the evidence that Ferring infringes claims 16 and 21 of United States Patent Number 10,675,309 ("the '309 patent");
- 3. No reasonable jury would have had a legally sufficient evidentiary basis to find that Finch/UMN proved by a preponderance of the evidence that any infringement by Ferring of the '914 patent, the '309 patent, and United States Patent Number 11,541,080 ("the '080 patent") was and is willful;
- 4. No reasonable jury would have had a legally sufficient evidentiary basis to find that Ferring had not proven by clear and convincing evidence that claim 16 of the '309 patent and claim 2 of the '080 patent are invalid as obvious;
- 5. No reasonable jury would have had a legally sufficient evidentiary basis to find that Ferring had not proven by clear and convincing evidence that claim 7 of the '914 patent is invalid for lacking written description support; and
- 6. No reasonable jury would have had a legally sufficient evidentiary basis to find that Finch/UMN presented sufficient evidence to support the damages awarded by the jury specifically with respect to the \$25,000,000 upfront payment.

In the alternative, Ferring requests remittitur of the damages award under Federal Rule of Civil Procedure 59.

Ferring will submit its brief in support of this motion on September 26, 2024, consistent with the Court's August 27, 2024 oral order setting the post-trial briefing schedule for this case.

Counsel for Ferring met and conferred with counsel for Finch/UMN but have been unable to reach agreement regarding this motion.

Dated: September 12, 2024

## Of Counsel:

Joshua P. Davis WOMBLE BOND DICKINSON (US) LLP 811 Main Street **Suite 3130** Houston, TX 77002 Telephone: (346) 998-7801 Joshua.P.Davis@wbd-us.com

Daralyn J. Durie Matthew Chivvis Rachel Dolphin Ramsey Fisher Clinton W. Ewell MORRISON & FOERSTER LLP 425 Market Street San Francisco, CA 94105-2482 Telephone: 415-268-6055 ddurie@mofo.com mchivvis@mofo.com rdolphin@mofo.com rfisher@mofo.com cewell@mofo.com

Whitney O'Byrne Sara Doudar MORRISON & FOERSTER LLP 701 Wilshire Boulevard Los Angeles, CA 90017 Telephone: 213-892-4345 wobyrne@mofo.com sdoudar@mofo.com

Sarah E. Brickey MORRISON & FOERSTER LLP WOMBLE BOND DICKINSON (US) LLP

## /s/ Mary W. Bourke

Mary W. Bourke (#2356) Dana K. Severance (#4869) Daniel M. Attaway (#5130) Zachary Murphy (#6881) 1313 North Market Street, Suite 1200 Wilmington, DE 19801 Telephone: (302) 252-4320 Mary.Bourke@wbd-us.com Dana.Severance@wbd-us.com Daniel.Attaway@wbd-us.com Zachary.Murphy@wbd-us.com

John B. Bourke (#6534) WOMBLE BOND DICKINSON (US) LLP 50 California Street, Suite 2750 San Francisco, CA 94111 Telephone: (415) 765-6267 Ben.Bourke@wbd-us.com

Attorneys for Ferring Pharmaceuticals Inc. and Rebiotix Inc.

4200 Republic Plaza 370 Seventeenth Street Denver, CO 80202-5638 Telephone: (303) 592-2267 sbrickey@mofo.com